Chinese Academy of Medical Sciences COVID-19 vaccine
Source: Wikipedia, the free encyclopedia.
Vaccine against COVID-19
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Other names | Covidful (Chinese: 科维福; pinyin: Kēwéifú) |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
|
Identifiers | |
DrugBank |
Chinese Academy of Medical Sciences COVID-19 vaccine, or IMBCAMS COVID-19 vaccine, traded as Covidful (Chinese: 科维福; pinyin: Kēwéifú), is a COVID-19 vaccine developed by Institute of Medical Biology, Chinese Academy of Medical Sciences [zh].
Clinical trials
In May 2020, Covidful started phase I/II clinical trial with 942 participants in China.[2]
In January 2021, Covidful started phase III clinical trials with 34,020 from Brazil and Malaysia.[3]
Authorizations
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
On 9 June 2021, The vaccine has been approved by the Chinese authorities.[1]
References
- ^ a b Liu R, Woo R (9 June 2021). "China builds new plant for IMBCAMS COVID-19 vaccine -state media". Reuters. Retrieved 15 June 2021.
- ^ Clinical trial number NCT04412538 for "Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19" at ClinicalTrials.gov
- ^ Clinical trial number NCT04659239 for "The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19" at ClinicalTrials.gov
External links
Scholia has a profile for Chinese Academy of Medical Sciences COVID-19 vaccine (Q106514790).